FNRC Stock DD 1st NRG Corp. 07/23/2014 09:40:43

Chasing the Holy Grail in Diabetes Treatment The pursuit of a true remedy for diabetes is almost like hunting for the mythical beast—a challenge that's left plenty of contenders biting the dust over the years. Yet, here's Paulex Bio jumping right into the fray with their groundbreaking PAL-119. They're not just peddling another temporary fix like most on the market;...

A New Stage for Creativity in London When the curtain rises on a fresh idea, it's often the unknowns that make or break a production. Now, with PRG Projects unveiling their spanking new Project Studio in London, the tech and creative worlds might just bridge their gap tighter than a stage curtain before showtime. London Welcomes PRG's Innovative Hub This isn't just...

TriMas Sheds Rapak: A Strategic Move Here's a twist worth dissecting: TriMas Corporation (NASDAQ: TRS) has offloaded its subsidiary Rapak, LLC to the German industrial packaging giant, Ringmetall SE. This isn't just a business shuffle—it's a calculated pivot with eyes on sharpening the core business blade. As they announced from Bloomfield Hills, Michigan, this move...

Gold Miners on the Move: Eye on i-80 Wake up and smell the gold, folks. i-80 Gold is ramping up to increase its yearly gold production targets, aiming for a hefty 150,000 to 200,000 ounces by 2028. Now, if you’ve been around the block like me, you know these are the kind of numbers that get investors either shifting in their chairs or springing to their feet. A Brief...

RD Technologies: Revving Up the Payment Game RD Technologies is at it again, jazzing up its game in the cross-border payments realm. One can almost smell the digits doing a tango across continents—particularly as Hong Kong's financial warriors set their sights on beefing up trade between Africa and Asia. New Alliances in the Payment Arena Here's a roadmap: Connect the...

If you’ve been watching the developments in the world of obesity treatments, Ascletis Pharma is a name you'd do well not to ignore. With ObesityWeek 2026 on the horizon, these folks aren’t just talking—they’re putting their preclinical cards on the table and they’re noteworthy. Unveiling Future Contenders Ascletis is gearing up to present some of their...

A New Senior Housing Era Begins in Channahon If there's one thing the affordable housing game loves, it's the mix of ambition and grit—both of which Lincoln Avenue Communities (LAC) brings to the table with The Talia. This latest project in Channahon, Illinois, marks their fourth groundbreaking in the state, cementing LAC's place as a key player in providing quality...

Picture a classroom without walls, the teacher always available, and students moving at their own pace. Sounds utopian, right? Well, Virtual Public School Expert Kim Dunbar is making sense of this approach at SC Whitmore School in Columbia, South Carolina, as she explains how this works in an online high school. Mastery-Based Learning: Beyond the Conventional Rigid...

Neurocrine's Triple-Digit Surge Neurocrine Biosciences is on a tear, pushing its revenue up to a jaw-dropping $1.1 billion in Q3 2026—a hefty 41% leap from the previous year. Frankly, you can't ignore those numbers. INGREZZA, which is practically becoming a cash cow, did $801 million alone, rising 17% year over year. This rides the wave of prescription surges and solid...

Recognition from Alma Mater Puts a Bow on a Storied Career When someone ventures out into the world and leaves a mark across continents, it’s a remarkable feat. It’s even more heartening when the place that helped shape them gets to extend a nod of recognition. Dr. Charles Huang, the mastermind behind Pasaca Capital, just unwound a new layer to his multicolored life...